GlassScriptPhysician profile
Emily Davidson
NPI 1548818198
$1,016.89
in general payments reported to CMS, 2019-2025
20 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $55.44 · 2023: $169 · 2024: $507 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.24 |
| Education | $205.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $132.01 | 2024 | Alunbrig, Fruzaqla |
| Intera Oncology, INC | $121.49 | 2024 | Intera |
| Lilly USA, LLC | $115.26 | 2025 | |
| Daiichi Sankyo INC. | $114.80 | 2023-2024 | Enhertu, Vanflyta, Injectafer |
| Janssen Biotech, INC. | $108.54 | 2023-2025 | Tecvayli, Akeega, Balversa |
| Idorsia Pharmaceuticals US INC | $59.90 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $49.87 | 2023-2025 | Opdivo |
| Stemline Therapeutics INC. | $42.46 | 2024-2025 | Orserdu |
| Puma Biotechnology, INC. | $34.19 | 2025 | |
| Corium, LLC | $25.94 | 2022-2023 | Azstarys |
| Taiho Oncology, INC. | $25.04 | 2024 | |
| Pfizer INC. | $24.25 | 2024 | |
| Grifols USA, LLC | $23.94 | 2023 | Gamunex-C |
| Genentech USA, INC. | $22.79 | 2023 | Ocrevus |
| Glaxosmithkline, LLC. | $22.68 | 2023 | Jemperli, Zejula |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.17 | 2025 | Lynparza, Keytruda |
| Astrazeneca Pharmaceuticals LP | $18.95 | 2025 | Calquence |
| Novartis Pharmaceuticals Corporation | $18.62 | 2025 | |
| Genzyme Corporation | $17.56 | 2024 | |
| Horizon Therapeutics Plc | $16.43 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.